

Ingevity Corporation (NGVT)

NA (Stock Price as of)

Price Target (6-12 Months): **NA**

Long Term: 6-12 Months

Zacks Recommendation:

(Since:)

Prior Recommendation: NA

Short Term: 1-3 Months

Zacks Rank: (1-5)

NA-NA

Zacks Style Scores:

VGM: NA

Value: NA

Growth: NA

Momentum: NA

Summary

Earnings estimates for Ingevity for the third quarter have been stable over the past month. The company is expected to gain from its strategy to pursue value-creating acquisitions. Ingevity has completed the successful repositioning of its Performance Chemicals business by reducing exposure to lower-margin end markets. Ongoing portfolio optimization, margin improvements and innovative growth initiatives support long-term growth. However, Ingevity faces headwinds from weak Advanced Polymer Technologies sales, tariff-related disruptions and softer global industrial demand. Lower auto production forecasts are likely to impact the Performance Materials segment, while Performance Chemicals and Advanced Polymer Technologies sales remain under pressure due to repositioning efforts and challenging demand conditions.

Data Overview

52 Week High-Low

20 Day Average Volume (sh)

Market Cap

YTD Price Change

Beta

Dividend / Div Yld

Industry

Zacks Industry Rank

Last EPS Surprise

Last Sales Surprise

EPS F1 Est- 4 week change

Expected Report Date

Earnings ESP

P/E TTM

P/E F1

PEG F1

P/S TTM

NA - NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

0.0%

NA

NA


NA

NA

Price, Consensus & Surprise⁽¹⁾



Sales and EPS Growth Rates (Y/Y %)⁽²⁾



Sales Estimates (millions of \$)⁽²⁾

	Q1	Q2	Q3	Q4	Annual*
2026					1,377 E
2025	284 A	365 A	333 A		1,344 E
2024	340 A	391 A	377 A	299 A	1,406 A

EPS Estimates⁽²⁾

	Q1	Q2	Q3	Q4	Annual*
2026					4.55 E
2025	0.99 A	1.39 A	1.31 A	0.91 E	4.05 E
2024	0.52 A	1.01 A	1.10 A	0.95 A	3.51 A

*Quarterly figures may not add up to annual.

(1) The data in the charts and tables, including the Zacks Consensus EPS and sales estimates, is as of .

(2) The report's text and the price target are as of 10/06/2025.

Overview

Based in North Charleston, SC, Ingevity Corporation is a global producer of high-performance activated carbon materials and specialty chemicals. The company provides innovative solutions through proprietary, formulated products. Ingevity started trading in May 2016 after its spinoff from the WestRock Company.

The company's products are used across a wide range of applications, including oil exploration and production, agrochemicals, asphalt paving, adhesives, lubricants, publication inks, coatings and automotive components that reduce gasoline vapor emissions.


Ingevity reports through two operating segments – Performance Chemicals and Performance Materials.

Performance Chemicals (43% of 2024 sales) – This segment mainly produces applications in three product families, namely, oilfield technologies, pavement technologies and industrial specialties. These products act as critical inputs in a range of high-performance applications, including printing inks, asphalt paving, adhesives, agrochemicals, lubricants and oil exploration and production.

Performance Materials (43%) – This segment includes process purifications and automotive technologies. Process purification makes activated carbon products for water, food, beverage and chemical purification applications. Automotive technologies make automotive carbon products that are used in gasoline vapor emission control systems in trucks, cars, boats and motorcycles.

The company, in March 2018, completed the buyout of Georgia-Pacific's pine chemicals business for \$310 million. The business makes pine-based tall oil fatty acids, tall oil rosin and tall oil rosin esters that are utilized in adhesives, cleaners, paints and other coatings, inks, metalworking, mining, oilfield, packaging and rubber processing.

In February 2019, Ingevity completed the purchase of the Capa caprolactone division of Perstorp Holding AB for roughly \$652.5 million. Capa is an international market leader in the manufacture and commercialization of caprolactone and high-value downstream derivatives, which include caprolactone thermoplastics, caprolactone polyols, caprolactone lactides and hexanediol.



Reasons To Buy:

- ▲ Ingevity is expected to gain from its strategy to pursue value-creating acquisitions. The acquisition of Georgia-Pacific's pine chemicals business has benefited the company through manufacturing optimization, lower logistics costs and leveraged procurement costs. The benefits are visible through the cost savings and margin expansion being witnessed. The acquisition of the Capa caprolactone business enabled the company to acquire a new technology platform to drive revenue and earnings growth. Capa has a strong and market-leading business that focuses on high-growth end-use applications. The acquisition of Ozark Materials will also strengthen the company's position in the paving construction industry and enable it to serve customers better.
- ▲ The company has completed the successful repositioning of its Performance Chemicals business by reducing exposure to lower-margin end markets. This was evident through its improved working capital, strong free cash flow and improving EBITDA. The company expects total savings from repositioning actions of roughly \$95-\$100 million. The successful repositioning actions resulted in EBITDA margins surging to approximately 20% in the most recent quarter, the highest in two years. The company also steers forward with its plans to optimize the portfolio by divesting in the Industrial Specialties business and crude tall oil (CTO) refinery.
- ▲ Ingevity is implementing several initiatives to drive long-term growth. The company has achieved its first commercial sales of Tall Oil Fatty Acid ("TOFA") in European biofuels, anticipating that this will open new opportunities and generate incremental yield. Additionally, Ingevity raised the production capacity of soy-based fatty acid at its Crossett facility, enhancing ability to meet the growing market demand. The company is also expanding the monomer production capacity of caprolactone in Warrington and increasing the polyol capacity at its DeRidder plant. Ingevity sees opportunities for increased testing and contributions to the methane value chain. The Pavement Technology business is expected to provide a significant boost, as the company is well-positioned to globalize and capitalize on this segment.

Strategic acquisitions strengthen technology capabilities and market reach. Successful repositioning, ongoing portfolio optimization and innovative growth initiatives support long-term growth.

Reasons To Sell:

- ▼ During the second quarter of 2025, Ingevity's Performance Chemicals division witnessed lower sales as a result of its repositioning actions. The repositioning efforts were aimed at exiting lower-margin end markets to lower CTO costs. Road technologies sales also went down initially, with some momentum recovery in June and July. Sales in Advanced Polymer Technologies continued to slump due to weak customer demand, especially in Europe and Asia, along with competitive pricing pressure. Margins were also hurt significantly, resulting in a bleak management outlook.
- ▼ The uncertain tariff impacts will require the company to be dynamic enough to execute a wide range of mitigation techniques. Although the company has plans laid down, successful execution might pose a challenge. Weak macroeconomic conditions due to disruptions caused by tariffs are expected to affect business and consumer sentiment in the near term, impacting demand for the company's products. Performance materials and Advanced Polymer Technologies segment face volume pressures and delayed contracts with anticipated disruptions in the near term.
- ▼ North America's auto production has been forecasted to improve slightly but will remain below prior-year levels. China might be the only market to witness year-over-year growth in auto production. These expectations are likely to adversely impact the Performance Materials segment.

Ingevity faces continued pressure from weak sales, tariff impacts and soft industrial demand, while lower auto production volumes are likely to affect Performance Materials.

Last Earnings Report

Ingevity's Q2 Earnings Surpass Estimates, Revenues Decline Y/Y

Ingevity recorded a second-quarter 2025 loss of \$146.5 million or a loss of \$4.02 per share. This compared favorably with a loss of \$283.7 million or a loss of \$7.81 per share in the year-ago quarter.

Excluding one-time items, adjusted earnings in the quarter were \$1.39 per share, up from \$1.01 a year ago. The figure beat the Zacks Consensus Estimate of \$1.02 per share.

Revenues fell 6.5% year over year to \$365.1 million in the quarter. This decline was due to lower sales in the Performance Chemicals segment.

Segmental Review

The Performance Chemicals division generated revenues of \$167.9 million in the reported quarter, down around 9.5% year over year. Road Technologies' product line sales of \$119.5 million were down 7.4%. Industrial Specialties' product line sales of \$48.4 million fell 14.2%, owing to the impact of the segment's repositioning measures, which were aimed at exiting lower-margin end markets. Earnings before interest, taxes, depreciation and amortization (EBITDA) for the segment rose 244% to \$32 million as a result of the successful implementation of the repositioning plans and cost savings, as well as lower raw material costs.

Revenues in the Performance Materials unit fell around 2.1% year over year to \$153.9 million. This was a result of lower sales in Asia and Europe due to tariff uncertainty. North America witnessed higher sales. Segment EBITDA was \$77.1 million, down 6.2% due to investments in innovation and a few one-time employee compensation costs.

Sales in the Advanced Polymer Technologies segment were down 9.6% to \$43.3 million. This downside was due to reduced customer demand, particularly in Europe. Segment EBITDA was \$0.9 million, down 90.8%, due to the planned extended outage in the second quarter.

Financials

The second-quarter operating cash flow was \$79 million, with free cash flow of \$66.8 million. There were no share repurchases during the quarter, leaving \$353.4 million remaining under the current \$500 million authorization. Net leverage improved to 3x from the previous quarter's 3.3x.

2025 Outlook Revised

Ingevity's focus will be on improving profitability and reducing leverage. With the current state of trade affairs in mind, Ingevity has raised the bottom end of its EBITDA guidance to incorporate the solid first-half results and improvement in North America auto production forecasts. Per the revised guidance, adjusted EBITDA has been updated to be between \$390 million and \$415 million compared with the previous expectation of \$380-\$415 million. Sales estimates are reaffirmed at between \$1.25 billion and \$1.40 billion.

FY Quarter Ending **12/31/2024**

Earnings Reporting Date	Nov 05, 2025
Sales Surprise	NA
EPS Surprise	NA
Quarterly EPS	NA
Annual EPS (TTM)	NA

Valuation

Ingevity's shares are up 53.3% over the trailing 12-month period. In the past year, the Zacks Chemicals-Specialty industry and the Zacks Basic Materials sector are down 4.7% and up 10.9%, respectively.

The S&P 500 index is up 21.8% in the past year.

The stock is currently trading at 5.01X trailing 12-month enterprise value-to EBITDA (EV/EBITDA) ratio, which compares to 12.3X for the Zacks sub-industry, 14.51X for the Zacks sector and 18.65X for the S&P 500 index.

Over the past five years, the stock has traded as high as 11.21X and as low as 3.12X, with a 5-year median of 7.7X.

Our Neutral recommendation indicates that the stock will perform in line with the market. Our \$58 price target reflects 13.09X forward 12-month earnings per share.


The table below shows a summary of valuation data for NGVT:

Valuation Multiples - NGVT					
		Stock	Sub-Industry	Sector	S&P 500
EV/EBITDA TTM	Current	5.01	12.3	14.51	18.65
	5-Year High	11.21	14.38	14.51	22.58
	5-Year Low	3.12	8.93	5.81	13.96
	5-Year Median	7.7	11.8	11.01	18.1
P/E F12M	Current	12.41	22.69	17.01	23.35
	5-Year High	16.07	25.4	17.01	23.58
	5-Year Low	6.41	14.25	7.98	15.72
	5-Year Median	11.01	22.63	12.76	21.17
P/B TTM	Current	16.62	3.39	2.99	8.81
	5-Year High	18.35	3.86	4.26	9.19
	5-Year Low	1.89	2.44	2.2	6.62
	5-Year Median	4.37	3.05	3.05	8.01

As of 10/03/2025

Source: Zacks Investment Research

Industry Analysis⁽¹⁾ Zacks Industry Rank: NA



Top Peers ⁽¹⁾

Company (Ticker)	Rec	Rank
Axalta Coating Systems (AXTA)	Neutral	3
Celanese Corporation (CE)	Neutral	3
Element Solutions Inc. (ESI)	Neutral	3
Koppers Holdings Inc. (KOP)	Neutral	3
Quaker Houghton (KWR)	Neutral	3
Cabot Corporation (CBT)	Underperform	5
Eastman Chemical Company (EMN)	Underperform	5
Valvoline (VVO)	Underperform	5

Industry Comparison⁽¹⁾ Industry: Chemical - Specialty

	NGVT	X Industry	S&P 500	AXTA	CBT	ESI
Zacks Recommendation (Long Term)	NA	-	-	Neutral	Underperform	Neutral
Zacks Rank (Short Term)		-	-	3	5	3
VGM Score	NA	-	-	B	A	C
Market Cap	1.78 B	1.90 B	37.69 B	6.43 B	3.28 B	5.90 B
# of Analysts	0	2	22	6	2	4
Dividend Yield	0.00%	0.49%	1.52%	0.00%	2.92%	1.31%
Value Score	NA	-	-	A	A	B
Cash/Price	0.05	0.08	0.04	0.09	0.08	0.10
EV/EBITDA	145.79	10.86	14.29	9.32	4.88	13.83
PEG Ratio	0.90	2.32	2.16	1.19	2.89	1.22
Price/Book (P/B)	13.09	1.69	3.28	2.77	1.93	2.21
Price/Cash Flow (P/CF)	3.08	11.85	14.45	8.17	5.94	11.61
P/E (F1)	12.43	18.28	19.75	12.06	8.51	16.74
Price/Sales (P/S)	1.39	1.57	2.99	1.25	0.88	2.36
Earnings Yield	NA%	5.16%	5.04%	8.29%	11.75%	5.98%
Debt/Equity	8.39	0.46	0.57	1.45	0.50	0.61
Cash Flow (\$/share)	16.11	2.43	8.99	3.69	10.39	2.10
Growth Score	NA	-	-	C	A	D
Hist. EPS Growth (3-5 yrs)	-9.88%	5.46%	8.17%	9.36%	16.85%	4.76%
Proj. EPS Growth (F1/F0)	15.38%	9.79%	8.30%	6.38%	0.00%	1.39%
Curr. Cash Flow Growth	118.95%	6.14%	7.00%	27.15%	0.55%	-9.11%
Hist. Cash Flow Growth (3-5 yrs)	14.85%	5.85%	7.32%	0.47%	14.83%	5.85%
Current Ratio	1.27	2.11	1.18	2.20	1.61	4.05
Debt/Capital	89.35%	34.61%	38.16%	59.26%	33.42%	37.85%
Net Margin	-5.14%	3.52%	12.75%	8.81%	8.91%	9.58%
Return on Equity	103.69%	9.83%	17.03%	24.92%	24.55%	14.01%
Sales/Assets	0.66	0.69	0.53	0.68	0.99	0.51
Proj. Sales Growth (F1/F0)	-4.40%	0.00%	5.53%	-2.80%	-0.80%	1.60%
Momentum Score	NA	-	-	C	C	A
Daily Price Chg	4.38%	2.68%	0.98%	5.05%	5.11%	6.13%
1 Week Price Chg	0.38%	-1.70%	-1.95%	4.32%	0.18%	-5.76%
4 Week Price Chg	-13.31%	-6.80%	-2.78%	3.86%	-13.50%	-6.80%
12 Week Price Chg	-15.11%	-10.24%	2.21%	-3.52%	-24.34%	-5.13%
52 Week Price Chg	2.06%	-17.73%	10.61%	-25.57%	-44.08%	-15.98%
20 Day Average Volume	315,983	340,880	3,031,286	5,453,434	526,893	2,915,791
(F1) EPS Est 1 week change	NA%	0.00%	0.00%	0.00%	0.00%	0.00%
(F1) EPS Est 4 week change	NA%	0.00%	0.32%	0.55%	-18.77%	0.87%
(F1) EPS Est 12 week change	NA%	-0.07%	0.58%	-0.05%	-17.58%	1.04%
(Q1) EPS Est Mthly Chg	NA%	-2.29%	-0.06%	-0.58%	-15.78%	-2.29%

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	NA
Growth Score	NA
Momentum Score	NA
VGM Score	NA

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless otherwise indicated in the report's first-page footnote. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.